New Brunswick-based health care giant Johnson & Johnson has entered into a definitive agreement to acquire clinical-stage biotechnology company Halda Therapeutics OpCo, Inc. for $3.05 billion in cash. The acquisition is set to significantly bolster J&J’s oncology pipeline with a highly differentiated, clinical-stage treatment for prostate cancer and a novel platform capable of targeting multiple solid tumors, including breast and lung cancers.
The acquisition underscores J&J’s nearly two decades of commitment to innovation in prostate cancer treatment, a disease projected to see new diagnoses reach 1.7 million globally by 2030.
The centerpiece of the deal is Halda’s proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform. This technology is designed to develop the next generation of oral, highly targeted therapies that enable the selective killing of cancer cells.
Halda’s lead candidate, HLD-0915, is a once-daily, clinical-stage therapy for prostate cancer. Its novel precision approach shows potential to overcome common mechanisms of resistance that cause many standard treatments to lose effectiveness over time—a critical unmet need in oncology.
“This acquisition further strengthens our deep oncology pipeline with an exciting lead asset in prostate cancer and a platform capable of treating multiple cancers and diseases beyond oncology, providing a potential mid- and long-term catalyst for growth,” Jennifer Taubert, executive vice president, Worldwide chairman, Innovative Medicine, Johnson & Johnson, said in a press release.
For the Garden State, the deal reinforces New Jersey’s status as a global hub for pharmaceutical and life sciences innovation, with J&J—a cornerstone of the state’s economy and research community—making a multi-billion-dollar investment in advanced therapeutics.
-
R&D Acceleration: J&J plans to accelerate the ongoing Phase 1/2 clinical trial of HLD-0915 and rapidly progress Halda’s pipeline, a process that will leverage J&J’s world-class R&D, commercial, and manufacturing capabilities centered in New Jersey.
-
Pipeline Growth: The acquisition, which includes several earlier candidates for breast, lung, and other tumor types, is viewed as a key driver for mid- and long-term growth for J&J’s Innovative Medicine sector.
-
Scientific Integration: J&J Executive Vice President Dr. John Reed, Ph.D., highlighted the immediate clinical promise: “Results seen with HLD-0915 demonstrate impressive preliminary efficacy and a strong early safety profile in prostate cancer. We are eager to accelerate the ongoing Phase 1/2 clinical trial of HLD-0915 and progress a pipeline of novel product candidates based on RIPTAC™ technology.”
The transaction is expected to close within the next few months, subject to antitrust clearance and other customary closing conditions. J&J anticipates a $0.15 dilution to Adjusted Earnings Per Share (EPS) in 2026 due to short-term financing and non-recurring charges.
